12.04.25 -- What You Need To Know About The Access Consortium Pathway

Through common sense and creative thinking, the industry can discover new ways to achieve success and sustainability in the biosimilar market.

Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

Learn how cross-functional teams streamline cell therapy manufacturing and releasing for Phase 1 trials to meet patient timelines and ensure safe delivery of personalized treatments.

Single-use technologies are reshaping biomanufacturing workflows. Discover the key stages of implementation and how strategic choices drive success across the entire production process.